HealthMore in Health→
Revolution Medicines highlights new KRAS pill data at AACR 2026
Key Takeaways
- Revolution Medicines highlighted new AACR 2026 data for a KRAS-targeting pancreatic cancer pill.
- The company framed the results as unusually strong, signaling confidence in the program.
- The supplied source does not include detailed efficacy or safety figures, so the update remains an early signal rather than a final verdict.
DE
DT Editorial Team··via statnews.com